by JANE ALLIN
With a fall in prescriptions and market growth, revenues of the Premarin family of drugs have fallen 3% in 2016.
So what does a 3% loss in the Premarin family of drugs represent?
In 2015, as well as several years previously, these drugs netted about a billion US dollars. The question now is whether this is significant.
Looking at the trend in sales figures since 2013 perhaps there is light at the end of the tunnel for the horses, albeit a distant and perhaps faint hope. http://www.pfizer.com/system/files/presentation/2015_Pfizer_Financial_Report.pdf
There has been a steady decrease in sales between 2013 and 2015 and now revenues are down another 3% in the current year.
A 3% decrease in revenues from 2015 represents an estimated profit margin for the Premarin family of about 987 million USD for 2016. When compared to 2013 this is a decline of approximately 9.6% in revenues or in dollar amounts 105 million USD.
Of their total revenue (~ 49 billion USD in 2015) this may not seem like a lot but it is an encouraging trend that we hope means that both women and their physicians are paying heed to the dangers of equine-derived HRT and prescribing alternatives, despite Pfizer’s aggressive ads promoting it.
What we don’t know is how large the drop in prescriptions really is. The revenues we see are of course dependent on the price of these drugs. If the costs have increased this means that prescriptions have declined even more so relative to 2013. The alternative of lower pricing options makes it more difficult to assess.
The saving factor here may be that we all know that Big Pharma is a money-making machine and trimming profits are not in their best interest.
Whatever the case, let’s hope this trend continues.
Spread the word.
The Horse Fund